학술논문
Lenvatinib治療におけるRelative dose intensityの問題点と体表面積補正dose intensity（DI/BSA ratio；DBR）の有用性 / Usefulness of dose intensity/body surface area ratio (DI/BSA ratio; DBR) rather than relative dose intensity in the lenvatinib treatment for hepatocellular carcinoma
Document Type
Journal Article
Author
Source
肝臓 / Kanzo. 2020, 61(3):129
Subject
Language
Japanese
ISSN
0451-4203
1881-3593
1881-3593
Abstract
Relative dose intensity (RDI) is the ratio between the delivered dose intensity and the standard dose. Maintaining high RDI has been shown to improve clinical outcomes in various cancers. The dose of lenvatinib was determined according to patient's weight (12 mg/day for ≥60 kg or 8 mg/day for <60 kg); therefore, RDI could not reflect the actual treatment intensity in some cases. Here, we evaluated the utility of dose intensity/body surface area ratio (DBR). The difference in PFS between patients with high RDI (≥0.67) and low RDI (p = 0.0534) was not significant, whereas patients with high DBR (≥240) showed significantly better PFS than those with low DBR (p < 0.0001). DBR may be more appropriately used in assessing the lenvatinib treatment intensity as compared with RDI.